{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:37:56Z","timestamp":1648622276400},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s12020-013-0163-0","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T21:42:54Z","timestamp":1389303774000},"page":"550-556","source":"Crossref","is-referenced-by-count":3,"title":["Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing\u2019s disease"],"prefix":"10.1007","volume":"47","author":[{"given":"Francesco","family":"Ferrau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cannavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"163_CR1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing\u2019s syndrome. Lancet 367, 1605\u20131617 (2006)","journal-title":"Lancet"},{"issue":"4","key":"163_CR2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1210\/jc.2012-3200","volume":"98","author":"X Bertagna","year":"2013","unstructured":"X. Bertagna, L. Guignat, Approach to the Cushing\u2019s disease patient with persistent\/recurrent hypercortisolism after pituitary surgery. J. Clin. Endocrinol. Metab. 98(4), 1307\u20131318 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"163_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.0.1490195","volume":"149","author":"S Cannavo","year":"2003","unstructured":"S. Cannavo, B. Almoto, C. Dall\u2019Asta, S. Corsello, R.M. Lovicu, E. De Menis, F. Trimarchi, B. Ambrosi, Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur. J. Endocrinol. 149(3), 195\u2013200 (2003)","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"163_CR4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93(7), 2454\u20132462 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"163_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"R. Pivonello, M.C. De Martino, P. Cappabianca, M. De Leo, A. Faggiano, G. Lombardi, L.J. Hofland, S.W. Lamberts, A. Colao, The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94(1), 223\u2013230 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"163_CR6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","volume":"15","author":"I Shimon","year":"2012","unstructured":"I. Shimon, L. Rot, E. Inbar, Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15(4), 608\u2013613 (2012)","journal-title":"Pituitary"},{"issue":"2","key":"163_CR7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-012-9668-1","volume":"42","author":"C Beglinger","year":"2012","unstructured":"C. Beglinger, K. Hu, Y. Wang, E. Bouillaud, C. Darstein, Y. Wang, P. Mohideen, Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 42(2), 366\u2013374 (2012)","journal-title":"Endocrine"},{"issue":"10","key":"163_CR8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366(10), 914\u2013924 (2012)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"163_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1358\/dot.2013.49.2.1915142","volume":"49","author":"RA Feelders","year":"2013","unstructured":"R.A. Feelders, W.W. de Herder, S.J. Neggers, A.J. van der Lely, L.J. Hofland, Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc.) 49(2), 89\u2013103 (2013)","journal-title":"Drugs Today (Barc.)"},{"issue":"4","key":"163_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11102-005-1404-x","volume":"7","author":"J Hoek van der","year":"2004","unstructured":"J. van der Hoek, S.W. Lamberts, L.J. Hofland, The role of somatostatin analogs in Cushing\u2019s disease. Pituitary 7(4), 257\u2013264 (2004)","journal-title":"Pituitary"},{"key":"163_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mce.2007.10.015","volume":"286","author":"LJ Hofland","year":"2008","unstructured":"L.J. Hofland, Somatostatin and somatostatin receptors in Cushing\u2019s disease. Mol. Cell. Endocrinol. 286, 199\u2013205 (2008)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"163_CR12","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"A. Ben-Shlomo, H. Schmid, K. Wawrowsky, O. Pichurin, E. Hubina, V. Chesnokova, N.A. Liu, M. Culler, S. Melmed, Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94(11), 4342\u20134350 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"843","key":"163_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/pgmj.72.843.53","volume":"72","author":"F Kelestimur","year":"1996","unstructured":"F. Kelestimur, C. Utas, O. Ozbakir, A. Sel\u00e7uklu, O. Kandemir, N. Ozcan, The effects of octreotide in a patient with Nelson\u2019s syndrome. Postgrad. Med. J. 72(843), 53\u201354 (1996)","journal-title":"Postgrad. Med. J."},{"issue":"Suppl 1","key":"163_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000314296","volume":"92","author":"LJ Hofland","year":"2010","unstructured":"L.J. Hofland, S.W. Lamberts, R.A. Feelders, Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(Suppl 1), 11\u201316 (2010)","journal-title":"Neuroendocrinology"},{"key":"163_CR15","doi-asserted-by":"crossref","unstructured":"Arregger, A.L., Cardoso, E.M., Sandoval, O.B., Monardes Tumilasci, E.G., Sanchez, R., Contreras, L.N.: Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update. Am. J. Ther. (2012) (Epub ahead of print)","DOI":"10.1097\/MJT.0b013e318255bc07"},{"key":"163_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"G.K. Stalla, S.J. Brockmeier, U. Renner, C. Newton, M. Buchfelder, J. Stalla, O.A. Muller, Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur. J. Endocrinol. 130, 125\u2013131 (1994)","journal-title":"Eur. J. Endocrinol."},{"key":"163_CR17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"J. van der Hoek, M. Waaijers, P.M. van Koetsveld, D. Sprij-Mooij, R.A. Feelders, H.A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J.E. Taylor, M.D. Culler, S.W. Lamberts, L.J. Hofland, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 289, 278\u2013287 (2005)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"163_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/JME-08-0110","volume":"42","author":"C Bruin de","year":"2009","unstructured":"C. de Bruin, R.A. Feelders, A.M. Waaijers, P.M. van Koetsveld, D.M. Sprij-Mooij, S.W. Lamberts, L.J. Hofland, Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids. J. Mol. Endocrinol. 42, 47\u201356 (2009)","journal-title":"J. Mol. Endocrinol."},{"issue":"8","key":"163_CR19","first-page":"2885","volume":"81","author":"F Vignati","year":"1996","unstructured":"F. Vignati, P. Loli, Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 81(8), 2885\u20132890 (1996)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"163_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12020-012-9846-1","volume":"44","author":"JD Carmichael","year":"2013","unstructured":"J.D. Carmichael, M. Fleseriu, Mifepristone: is there a place in the treatment of Cushing\u2019s disease? Endocrine 44, 20\u201332 (2013)","journal-title":"Endocrine"},{"issue":"12","key":"163_CR21","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593\u20135602 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"163_CR22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1590\/S0004-27302007000800019","volume":"51","author":"A Utz","year":"2007","unstructured":"A. Utz, B.M. Biller, The role of bilateral inferior petrosal sinus sampling in the diagnosis of Cushing\u2019s syndrome. Arq. Bras. Endocrinol. Metabol. 51(8), 1329\u20131338 (2007)","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"issue":"4","key":"163_CR23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MED.0b013e3283631809","volume":"20","author":"LK Nieman","year":"2013","unstructured":"L.K. Nieman, Update in the medical therapy of Cushing\u2019s disease. Curr. Opin. Endocrinol. Diabetes Obes. 20(4), 330\u2013334 (2013)","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"4","key":"163_CR24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1507\/endocrj.K08E-186","volume":"56","author":"T Tateno","year":"2009","unstructured":"T. Tateno, M. Kato, Y. Tani, K. Oyama, S. Yamada, Y. Hirata, Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr. J. 56(4), 579\u2013584 (2009)","journal-title":"Endocr. J."},{"issue":"2","key":"163_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2011-1264","volume":"97","author":"C Bruin de","year":"2012","unstructured":"C. de Bruin, L.J. Hofland, L.K. Nieman, P.M. van Koetsveld, A.M. Waaijers, D.M. Sprij-Mooij, M. van Essen, S.W.J. Lamberts, W.W. de Herder, R.A. Feelders, Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing\u2019s syndrome due to ectopic adrenocorticotropin secretion. J. Clin. Endocrinol. Metab. 97(2), 455\u2013462 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"163_CR26","doi-asserted-by":"crossref","unstructured":"van der Pas, R., Feelders, R.A., Gatto, F., de Bruin, C., Pereira, A.M., van Koetsveld, P.M., Sprij-Mooij, D.M., Waaijers, A.M., Dogan, F., Schulz, S., Kros, J.M., Lamberts, S.W.J., Hofland, L.J.: Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J. Clin. Endocrinol. Metab. (2013) (Epub ahead of print)","DOI":"10.1210\/jc.2013-1987"},{"key":"163_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","volume":"13","author":"B Ambrosi","year":"1990","unstructured":"B. Ambrosi, D. Bochicchio, C. Fadin, P. Colombo, G. Faglia, Failure of somatostatin and octreotide to acutely affect the hypothalamic\u2013pituitary\u2013adrenal function in patients with corticotropin hypersecretion. J. Endocrinol. Invest. 13, 257\u2013261 (1990)","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"163_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0002-9343(93)90283-U","volume":"95","author":"NJ Woodhouse","year":"1993","unstructured":"N.J. Woodhouse, S. Dagogo-Jack, M. Ahmed, R. Judzewitsch, Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing\u2019s syndrome. Am. J. Med. 95(3), 305\u2013308 (1993)","journal-title":"Am. J. Med."},{"issue":"3","key":"163_CR29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-63-3-639","volume":"63","author":"X Bertagna","year":"1986","unstructured":"X. Bertagna, C. Bertagna, M.H. Laudat, J.M. Husson, F. Girard, J.P. Luton, Pituitary\u2013adrenal response to the antiglucocorticoid action of RU 486 in Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 63(3), 639\u2013643 (1986)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"163_CR30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","volume":"157","author":"S Johanssen","year":"2007","unstructured":"S. Johanssen, B. Allolio, Mifepristone (RU 486) in Cushing\u2019s syndrome. Eur. J. Endocrinol. 157, 561\u2013569 (2007)","journal-title":"Eur. J. Endocrinol."},{"key":"163_CR31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"F. Castinetti, M. Fassnacht, S. Johanssen, M. Terzolo, P. Bouchard, P. Chanson, C. Do Cao, I. Morange, A. Pico, S. Ouzounian, J. Young, S. Hahner, T. Brue, B. Allolio, B. Conte-Devolx, Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur. J. Endocrinol. 160, 1003\u20131010 (2009)","journal-title":"Eur. J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-0163-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-013-0163-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-0163-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:56:46Z","timestamp":1559440606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-013-0163-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s12020-013-0163-0","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}